OSTX
OS TherapiesยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OSTX
Os Therapies Incorporated
A clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors
Biological Technology
04/12/2018
08/01/2024
American Stock Exchange
4
12-31
Common stock
115 Pullman Crossing Road, Suite 103 , Grasonville, Maryland 21638
--
OS Therapies Incorporated was incorporated in Delaware on April 12, 2018. The Company is a clinical-stage biopharmaceutical company focused on the identification, development and commercialization of osteosarcoma and other solid tumor treatments. They are currently seeking to respond to the call for new therapies with their main core product candidate, OST-HER2 (also known as OST31-164). They intend to use this product candidate to expand their pipeline from osteosarcoma to other solid tumors with the same mechanism of recurrence, including breast, esophageal and lung cancer.
Company Financials
EPS
OSTX has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.12, missing expectations. The chart below visualizes how OSTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
